Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer [Phase 2]
This Phase 2 trial evaluating apalutamide and abiraterone acetate in African American and Caucasian men with metastatic castration-resistant…
-
CLINICAL_TRIALS trial_result · 2025-09-11Clinical Trial Update: Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer [Phase 2]
This clinical trial update describes a Phase 2 study evaluating schedule de-escalation of 177Lu-PSMA-617 for metastatic castration-resistant…
-
CLINICAL_TRIALS trial_result · 2025-09-09Clinical Trial Update: A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer [Phase 2]
This Phase 2 trial update reports completion of a study evaluating the combination of Triamcinolone with a GnRH analog in patients with cast…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: A Study of NX-1607 in Adults With Advanced Malignancies [Phase 1]
A Phase 1 study evaluating NX-1607 in adults with advanced malignancies is actively recruiting across multiple tumor types, including ovaria…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) [Phase 1]
This is a Phase 1 trial (PRODIGY-2) evaluating personalized versus fixed-activity 177Lu-PSMA-617 radiopharmaceutical therapy for metastatic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
An observational study evaluating the long-term safety of Radium-223 dichloride (Xofigo) for metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer [Phase 2]
A Phase 2 clinical trial compares stereotactic body radiotherapy to standard of care for oligoprogressive metastatic prostate cancer, curren…
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics
A clinical trial from Anhui Medical University aims to study castration-resistant prostate cancer progression and immune interactions in met…
-
EMA approval · 2025-08-29EMA Authorised: Nubeqa (darolutamide) — Bayer AG
The EMA authorised Nubeqa (darolutamide) for use in castration-resistant prostate cancer, expanding the drug's EU indication for Bayer AG as…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of metastatic castration-resistant prosta…
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: Re-treatment 225Ac-J591 for mCRPC [EARLY_Phase 1]
An early-phase (Phase 1) trial evaluating re-treatment with Actinium-225 labeled J591 for metastatic castration-resistant prostate cancer ha…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T [Phase 2]
A Phase 2 clinical trial is evaluating treating metastatic castration-resistant prostate cancer with PROVENGE (sipuleucel-T) plus one infusi…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial comparing cabazitaxel with or without carboplatin to 177Lu-PSMA-617 in metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]
ClinicalTrials.gov update describes a Phase 1/2 trial of FOR46 in combination with enzalutamide for metastatic castration-resistant prostate…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC [Phase 2]
A Phase II clinical trial evaluating the safety, efficacy, and pharmacokinetics of YL201 in metastatic castration-resistant prostate cancer …
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) [Phase 2]
Phase 2 clinical trial evaluating dosimetry, randomized dose optimization, dose escalation, and efficacy of Ac-225 Rosopatamab Tetraxetan in…
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 1]
This entry describes a Phase 1 clinical study evaluating the safety, tolerability, and preliminary efficacy of [225Ac]Ac-PSMA-XT Injection i…
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA [Phase 2]
Phase 2 clinical trial evaluating darolutamide with consolidation radiotherapy in advanced PSMA-detected prostate cancer; the study is curre…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Carboplatin or Olaparib for BRcA Deficient Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating carboplatin or olaparib in BRCA-deficient metastatic castration-resistant prostate cancer; the study is cu…
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA [Phase 2]
Phase 2 clinical trial evaluating treatment optimization for metastatic castration-resistant prostate cancer using analysis of circulating t…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This ClinicalTrials.gov update reports the completion of a Phase 1 study evaluating relugolix in men with metastatic castration-sensitive an…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update on cabozantinib alone or with atezolizumab for locally advanced or metastatic solid tumors; the study lists mu…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Liquid Biopsy Under PSMA Radioligand Therapy
A clinical trial conducted by Würzburg University Hospital is investigating the use of liquid biopsy in patients with metastatic castration-…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating the combination of ipilimumab with abiraterone acetate plus prednisone in …
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A prospective Phase 1/2 clinical trial is evaluating 225Ac-LNC1011 for metastatic castration-resistant prostate cancer and is currently recr…